[go: up one dir, main page]

HK1250626A1 - 借助塞里班土单抗的组合治疗 - Google Patents

借助塞里班土单抗的组合治疗 Download PDF

Info

Publication number
HK1250626A1
HK1250626A1 HK18110002.5A HK18110002A HK1250626A1 HK 1250626 A1 HK1250626 A1 HK 1250626A1 HK 18110002 A HK18110002 A HK 18110002A HK 1250626 A1 HK1250626 A1 HK 1250626A1
Authority
HK
Hong Kong
Prior art keywords
seribantumab
combination treatments
cancer
methods
combination
Prior art date
Application number
HK18110002.5A
Other languages
English (en)
Inventor
Bambang ADIWIJAYA
Akos CZIBERE
Rachel C. NERING
Gavin Macbeath
Original Assignee
Merrimack Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrimack Pharmaceuticals, Inc. filed Critical Merrimack Pharmaceuticals, Inc.
Publication of HK1250626A1 publication Critical patent/HK1250626A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK18110002.5A 2015-04-17 2016-04-15 借助塞里班土单抗的组合治疗 HK1250626A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562149271P 2015-04-17 2015-04-17
US62/149,271 2015-04-17
PCT/US2016/027933 WO2016168730A1 (en) 2015-04-17 2016-04-15 Combination treatments with seribantumab

Publications (1)

Publication Number Publication Date
HK1250626A1 true HK1250626A1 (zh) 2019-01-11

Family

ID=55854801

Family Applications (2)

Application Number Title Priority Date Filing Date
HK18110002.5A HK1250626A1 (zh) 2015-04-17 2016-04-15 借助塞里班土单抗的组合治疗
HK18108183.0A HK1248539A1 (zh) 2015-04-17 2016-04-15 借助塞里班土单抗的组合治疗

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK18108183.0A HK1248539A1 (zh) 2015-04-17 2016-04-15 借助塞里班土单抗的组合治疗

Country Status (13)

Country Link
US (1) US20160303232A1 (zh)
EP (1) EP3283068A1 (zh)
JP (1) JP2018513155A (zh)
KR (1) KR20170137886A (zh)
CN (1) CN107750165A (zh)
AU (1) AU2016248329A1 (zh)
CA (1) CA2983008A1 (zh)
EA (1) EA201792294A1 (zh)
HK (2) HK1250626A1 (zh)
IL (1) IL255092A0 (zh)
MA (1) MA45420A (zh)
SG (1) SG11201708491PA (zh)
WO (1) WO2016168730A1 (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3087394A2 (en) 2013-12-27 2016-11-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
WO2017161009A1 (en) * 2016-03-16 2017-09-21 Merrimack Pharmaceuticals, Inc. Dosage and administration of combination therapies comprising targeted antibodies uses and methods of treatment
CA3050133A1 (en) * 2017-01-26 2018-08-02 Surrozen, Inc. Tissue-specific wnt signal enhancing molecules and uses thereof
AU2019301633A1 (en) 2018-07-09 2021-01-28 Surrozen Operating, Inc. Tissue-specific Wnt signal enhancing molecules and uses
TW202233656A (zh) 2020-11-16 2022-09-01 美商蘇羅森營運公司 肝特異性wnt訊號增強分子及其用途
CN115976196B (zh) * 2022-12-16 2024-12-06 深圳市人民医院 ErbB3作为肺动脉高压生物标志物和治疗靶点的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170134771A (ko) * 2005-01-21 2017-12-06 제넨테크, 인크. Ｈｅｒ 항체의 고정 용량 투여법
US20080038725A1 (en) 2005-06-20 2008-02-14 Yuling Luo Methods of detecting nucleic acids in individual cells and of identifying rare cells from large heterogeneous cell populations
CN101674846B (zh) * 2007-02-16 2014-07-02 梅里麦克制药股份有限公司 ErbB3抗体及其用途
EP2318548B1 (en) 2008-08-15 2013-10-16 Merrimack Pharmaceuticals, Inc. Methods and systems for predicting response of cells to a therapeutic agent
US8895001B2 (en) 2010-03-11 2014-11-25 Merrimack Pharmaceuticals, Inc. Use of ErbB3 inhibitors in the treatment of triple negative and basal-like breast cancers
AU2011255238B2 (en) 2010-05-21 2015-06-04 Silver Creek Pharmaceuticals, Inc. Bi-specific fusion proteins
SG186889A1 (en) * 2010-07-09 2013-02-28 Exelixis Inc Combinations of kinase inhibitors for the treatment of cancer
WO2012103341A1 (en) 2011-01-27 2012-08-02 Merrimack Pharmaceuticals, Inc. Treatment of advanced solid stage tumors using anti-erbb3 antibodies
EA201300996A1 (ru) 2011-03-11 2014-01-30 Мерримак Фармасьютикалс, Инк. Использование ингибиторов рецепторов семейства egfr в лечении гормонорезистентного рака молочной железы
CN103429262A (zh) * 2011-03-15 2013-12-04 梅里麦克制药股份有限公司 克服对erbb途径抑制剂的抗性
KR20140063578A (ko) * 2011-06-30 2014-05-27 메리맥 파마슈티컬즈, 인크. 부인과 암들의 치료를 위해 파크리탁셀과 조합한 항-ｅｒｂｂ３ 항체들
WO2013023043A2 (en) 2011-08-10 2013-02-14 Merrimack Pharmaceuticals, Inc. Treatment of advanced solid tumors using combination of anti-erbb3 immunotherapy and selected chemotherapy
WO2013138371A1 (en) 2012-03-12 2013-09-19 Merrimack Pharmaceuticals, Inc. Methods for treating pancreatic cancer using combination therapies comprising an anti-erbb3 antibody
WO2015048793A2 (en) * 2013-09-30 2015-04-02 Daiichi Sankyo Co., Ltd. Nucleic acid biomarker and use thereof
EP3087394A2 (en) * 2013-12-27 2016-11-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies

Also Published As

Publication number Publication date
IL255092A0 (en) 2017-12-31
KR20170137886A (ko) 2017-12-13
MA45420A (fr) 2019-05-01
EA201792294A1 (ru) 2018-03-30
JP2018513155A (ja) 2018-05-24
WO2016168730A1 (en) 2016-10-20
CN107750165A (zh) 2018-03-02
US20160303232A1 (en) 2016-10-20
SG11201708491PA (en) 2017-11-29
EP3283068A1 (en) 2018-02-21
CA2983008A1 (en) 2016-10-20
HK1248539A1 (zh) 2018-10-19
AU2016248329A1 (en) 2017-11-09

Similar Documents

Publication Publication Date Title
PH12018502429A1 (en) Antibody molecules for cancer treatment
MX2018014175A (es) Conjugados de anticuerpo-fármaco anti-cmet y métodos para su uso.
HK1250626A1 (zh) 借助塞里班土单抗的组合治疗
WO2013177187A3 (en) Synergistic tumor treatment with extended-pk il-2 and therapeutic agents
MX2018008426A (es) Combinaciones anti-egfr para tratar tumores.
MX2015012922A (es) Tratamiento del cancer usando anticuerpos que se unen a grp78 en la superficie celular.
WO2016025635A3 (en) Combination therapy for treating cancer
EA201992251A1 (ru) Противораковые вакцины и способы лечения с их применением
HK1249052A1 (zh) 治疗与ras突变相关的癌症的方法
GEP20217317B (en) Combination therapy for the treatment of cancer
JO3735B1 (ar) مركبات ألكين بها استبدال رباعي واستخداماتها
HK1248588A1 (zh) 用於癌症治疗中的天花疫苗
AU2015249633A8 (en) Methods of treating early breast cancer with Trastuzumab-MCC-DM1 and Pertuzumab
WO2015009726A3 (en) Medical uses of cd38 agonists
NZ756730A (en) Combination therapy with an anti-axl antibody-drug conjugate
MX2018008427A (es) Combinaciones anti-cd20 para tratar tumores.
SG10201902664RA (en) Combination therapy for treating cancer
EA201591977A1 (ru) Противораковая терапия анти-egfr антителами, имеющими низкое фукозилирование
BR112017018964A2 (pt) uso de plinabulin e métodos para tratar tumor cerebral
WO2017079570A3 (en) Splise-switching oligonucleotides and methods of use
EP4552698A3 (en) Methods of treating prostate cancer
HK1258319A1 (zh) 癌症疗法
MX2020001727A (es) Terapia de combinacion.
MX2020005473A (es) Anticuerpos humanizados que se dirigen al factor tisular humano.
PH12018500254A1 (en) Combinations of an ox40 antibody and a tlr4 modulator and uses thereof